EUMETSAT Moodle

Therapeutic antibodies are highly regarded for their high affinity, specificity, low immunogenicity, and ability to target a wide range of biological molecules. Currently, mammalian cells, including Sp2/0, NS0, HEK293, and CHO cells, are primarily used for the production of therapeutic antibodies, with CHO cells accounting for over 70% of the production due to their complex posttranslational modification capabilities.

CHO cells are widely chosen for several reasons:

• Similar posttranslational modifications to human cells.
• High-density growth in serum-free and chemically defined suspension culture media.
• Efficient extracellular secretion of products, simplifying downstream purification processes.
• Minimal secretion of endogenous proteins, reducing purification complexity.
• High-level protein expression during extended fermentation periods.

Recombinant antibody production is a key technology for the commercialization of monoclonal antibody drugs, enabling the stable production of large quantities of high-quality antibodies using antibody gene sequences.